GT Biopharma Inc (GTBP)

GT Biopharma's stock price has significantly declined in the past six months. Shareholders have experienced substantial dilution, with total shares outstanding growing significantly. The company submitted an Investigational New Drug (IND) application for GTB-5550 TriKE. Zacks upgraded GT Biopharma to "Buy". The company has reported full-year and quarterly results, with the next earnings report expected around May 13, 2026.

There is no specific information available to indicate demand seasonality for GT Biopharma, Inc.'s products or services. As a clinical-stage biopharmaceutical company, its revenue is not yet primarily driven by commercial product sales, which typically exhibit seasonality.

GT Biopharma, Inc. is a clinical-stage immuno-oncology company focused on developing innovative therapies using its TriKE technology to enhance the cancer-killing abilities of natural killer cells. The company's product candidates include GTB-3650, currently in Phase 1 trials targeting CD33+ hematologic cancers; GTB-5550, also in Phase 1 trials targeting B7-H3 solid tumors; and GTB-7550, a pre-clinical stage product for lupus and other autoimmune disorders. GT Biopharma is also working on Tetra-specific Killer Engager constructs and has a worldwide license agreement with the University of Minnesota for TriKE technology.

GT Biopharma, Inc. is headquartered in San Francisco, California, and was incorporated in 1965. The company focuses on the development and commercialization of novel immuno-oncology products primarily in the United States.

GT Biopharma's brand reputation has shown mixed signals. While Zacks upgraded the stock to "Buy", Danelfin's AI model gave GTBP a "Sell" rating. Analyst sentiment suggests a significant potential increase from the current price, although the average price target has been revised downward. The company actively participates in industry conferences to present its developments.

GT Biopharma, Inc. is primarily owned by retail investors, followed by institutional shareholders and company insiders. The largest individual shareholder is Michael Martin Breen. Other major owners include Manu Ohri, Citadel Advisors LLC, Scientech Research LLC, and Seacrest Wealth Management, Llc, along with other institutional owners.